MSD GCC Expands Oncology Research Partnership with Abu Dhabi DoH


MSD GCC’s new memorandum of understanding (MoU) with The Department of Health Abu Dhabi (DoH) aims to advance research into breast and lung cancer. The deal, signed at the BIO International Convention 2023, marks the continuation of a long-term collaboration between the two entities.


Present at the signing were H.E. Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi and Jenelle Krishnamoorthy, VP Global Public Policy and Government Relations at MSD, while the MoU was signed by Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the DoH and Ashraf Mallak, Managing Director of MSD GCC.


Within the framework of their renewed partnership, the two parties will work together to initiate two observational research studies in the field of oncology, explicitly targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The studies aim to advance the ability to address the healthcare challenges associated with these diseases and improve patient outcomes.


Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi (DoH) said: “As we navigate the complexities of healthcare challenges, we remain focused on expanding collaboration with global partners who share our vision of advancing healthcare for all. Under the directives of our wise leadership, we are proud to renew our cooperation with MSD GCC, a long-standing partner that has been part of the Emirate’s healthcare journey. Through this agreement, we will leverage collective expertise, resources and knowledge to address pressing healthcare challenges.”


Dr Al Mannaei added: “Abu Dhabi is leading the transformation of the regional healthcare ecosystem by leveraging sciences and technology, positioning itself as a life science hub and an incubator for innovation on the global stage. Our research will pave the way for innovative treatments and interventions while fostering breakthrough diagnosis and solutions for patients around the world.”


Commenting on the agreement, Ashraf Mallak, Managing Director of MSD in the GCC, said: “The Department of Health Abu Dhabi has had exceptional efforts in establishing a healthcare system that stands as a global model of innovation and sustainability. Their forward-thinking approach, embracing advanced technology and fostering research and development, has led to the advancement of public health in the Emirate.”


He continued: “It is with great pride that MSD joins hands with the DoH at the BIO Convention. With this renewed collaboration, we are embarking on two important observational research studies in two prevalent cancers in the UAE: lung and breast cancer. Through these studies, we aim to make a meaningful impact on patient outcomes and contribute to the UAE’s vision for healthcare. This agreement reaffirms our commitment to driving medical progress to benefit patients in UAE.”


During the signing, DoH and MSD reiterated the importance of public-private partnerships to have a meaningful impact on the enhancement of healthcare services, with such collaborations bringing together the entities’ collective expertise and resources in medical research and patient care. The studies conducted by DoH and MSD will commence following a feasibility stage that ensures the necessary preparations are in place.


Read PharmaBoardroom’s 2021 conversation with Ashraf Mallak here


Related Content

Latest Report